Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial

Markus Joerger,Alwin D. R. Huitema,Stephan Krahenbuhl,Jan H. M. Schellens,Thomas Cerny,Michele Reni,Emanuele Zucca,F. Cavalli,A.J.M. Ferreri

Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial

2010

Markus Joerger
Alwin D. R. Huitema
Stephan Krahenbuhl
Jan H. M. Schellens
Thomas Cerny
Michele Reni
Emanuele Zucca
F. Cavalli
A.J.M. Ferreri

Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic–pharmacodynamic analysis from the IELSG no. 20 trial

Keywords:

Lymphoma
Medicine
Clinical trial
Immunology
Pathology
Area under the curve
Survival analysis
Cytarabine
Antimetabolite
Chemotherapy
Methotrexate
Population
Pharmacodynamics
Hazard ratio
Primary central nervous system lymphoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations